anti human ifn γ mab  (Mabtech Inc)

Journal: iScience

Article Title: Distinct CD8 + T cell types associated with COVID-19 severity in unvaccinated HLA-A2 + patients

doi: 10.1016/j.isci.2026.115880

Figure Lengend Snippet: Information on 11 selected HLA-A2-binding 9-mer peptides derived from the SARS-CoV-2 genome (A) Workflow of HLA-A2-binding peptide prediction with NETMHCpan4.1 and IFN-γ ELISpot assay of PBMCs from 24 patients with COVID-19 using 31 predicted peptides ( and ). (B) Homology of 11 selected peptides among SARS-CoV-2 variants and other strains (as indicated). “YES” indicates that more than 90% of epitope sequences matched within 200 selected peptide sequences from the database . Otherwise, the % of matched sequences is shown. “NO” indicates no matched sequences. (C) Information on the SARS-CoV-2 genome and mapping of 11 selected peptides on its genome.

Article Snippet: anti-human-IFN-γ antibody , MABTECH , Cat# 3420-3-250; RRID: AB_907283.

Techniques: Binding Assay, Derivative Assay, Enzyme-linked Immunospot

Journal: iScience

Article Title: Distinct CD8 + T cell types associated with COVID-19 severity in unvaccinated HLA-A2 + patients

doi: 10.1016/j.isci.2026.115880

Figure Lengend Snippet: IFN-γ ELISpot of CD8 + T cells in PBMCs from HLA-A2 + patients with COVID-19 using selected SARS-CoV-2 peptides (A) Cross-sectional ELISpot assay of HLA-A2-restricted CD8 + T cell responses against 11 selected peptides in PBMCs from 26 patients with mild, 8 with moderate, and 8 with severe COVID-19, respectively. (B) Log10-transformed mean spot-forming cell (SFC) counts (log10[Mean SFC +1]) per patient across 11 peptides in patients with mild, moderate, and severe COVID-19. Each point represents the mean response for one patient across 11 peptides ( n = 42 patients). A +1 pseudocount is added before the log10 transformation to accommodate zero values. Statistical comparisons were performed using a negative binomial mixed-effects model with Holm-Bonferroni correction for multiple comparisons. NS: not significant. (C) Longitudinal ELISpot assay of HLA-A2-restricted CD8 + T cell responses against selected peptides in PBMCs from patients with mild and moderate COVID-19 (as indicated).

Article Snippet: anti-human-IFN-γ antibody , MABTECH , Cat# 3420-3-250; RRID: AB_907283.

Techniques: Enzyme-linked Immunospot, Transformation Assay

Journal: Molecular Therapy Advances

Article Title: Systems vaccinology analysis of saRNA immunization identifies an acute innate immune signature correlated with adaptive immunity

doi: 10.1016/j.omta.2026.201706

Figure Lengend Snippet: Adaptive immune responses to vaccination correlate weakly with innate responses 24 h after prime immunization Adaptive immune response data are presented from all participants pooled (A–C) or from participants separated into those who received 1 or 5 μg doses (D–F). (A and D) Anti-Spike (S) IgG (ng/mL) in sera from participants receiving two doses of LNP-saRNA at various time points after enrollment. (B and E) Pseudoneutralizing antibody IC50 from participants receiving two doses of LNP-saRNA; responses are shown at 6 weeks after enrollment against Wuhan, Delta, and Omicron spike-expressing pseudoviruses. (C and F) IFN-γ spot forming units (SFU) per million cells (ELISpot) from PBMC stimulated with SARS-CoV-2 spike peptide pools. (G) Correlation between V2a chemokine levels and the last visit antibody response. (H) Correlation between V2a cell levels and the last visit antibody response. Points represent individual participants, bars represent median ± interquartile range (A–F); points represent individual participants.

Article Snippet: Plates were then washed and incubated for 2 h at room temperature with 1 μg/mL mouse-anti-human IFN-γ (Mabtech).

Techniques: Expressing, Enzyme-linked Immunospot